Optimizing chemoradiation in locally advanced non-small-cell lung cancer

Walter J. Curran, Hak Choy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gemcitabine (Gemzar) has demonstrated activity in a broad range of solid tumors with good tolerance. In combined-modality therapy, gemcitabine has achieved response rates ranging between 30% and 60% in patients with non-small-cell lung cancer. Initial trials of gemcitabine and radiation showed that the fields and volume of radiation as well as the dose of gemcitabine should be managed carefully so as to optimize the radiosensitizing properties of this agent. The Cancer and Leukemia Group B conducted a phase III trial in patients with unresectable stage III non-small-cell lung cancer. A total of 187 patients were randomized to one of three cisplatin (Platinol)-based combinations (with gemcitabine,paclitaxel [Taxol], or vinorelbine [Navelbine]) as induction therapy followed by concomitant chemoradiation. At a median follow-up of 9 months, the median survival for all patients was 18 months and the median progression-free survival was 10 months. The trial demonstrated that the combination of gemcitabine and cisplatin could be administered successfully as induction therapy without affecting concurrent administration of gemcilabine/cisplatin with radiation.

Original languageEnglish (US)
Pages (from-to)43-45
Number of pages3
JournalOncology
Volume15
Issue number3 SUPPL. 6
StatePublished - 2001

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Radiation
Paclitaxel
Radiation-Sensitizing Agents
Combined Modality Therapy
Disease-Free Survival
Neoplasms
Leukemia

ASJC Scopus subject areas

  • Oncology

Cite this

Optimizing chemoradiation in locally advanced non-small-cell lung cancer. / Curran, Walter J.; Choy, Hak.

In: Oncology, Vol. 15, No. 3 SUPPL. 6, 2001, p. 43-45.

Research output: Contribution to journalArticle

Curran, Walter J. ; Choy, Hak. / Optimizing chemoradiation in locally advanced non-small-cell lung cancer. In: Oncology. 2001 ; Vol. 15, No. 3 SUPPL. 6. pp. 43-45.
@article{46e02f2f70cc4e25b93bb8afa387dbf6,
title = "Optimizing chemoradiation in locally advanced non-small-cell lung cancer",
abstract = "Gemcitabine (Gemzar) has demonstrated activity in a broad range of solid tumors with good tolerance. In combined-modality therapy, gemcitabine has achieved response rates ranging between 30{\%} and 60{\%} in patients with non-small-cell lung cancer. Initial trials of gemcitabine and radiation showed that the fields and volume of radiation as well as the dose of gemcitabine should be managed carefully so as to optimize the radiosensitizing properties of this agent. The Cancer and Leukemia Group B conducted a phase III trial in patients with unresectable stage III non-small-cell lung cancer. A total of 187 patients were randomized to one of three cisplatin (Platinol)-based combinations (with gemcitabine,paclitaxel [Taxol], or vinorelbine [Navelbine]) as induction therapy followed by concomitant chemoradiation. At a median follow-up of 9 months, the median survival for all patients was 18 months and the median progression-free survival was 10 months. The trial demonstrated that the combination of gemcitabine and cisplatin could be administered successfully as induction therapy without affecting concurrent administration of gemcilabine/cisplatin with radiation.",
author = "Curran, {Walter J.} and Hak Choy",
year = "2001",
language = "English (US)",
volume = "15",
pages = "43--45",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3 SUPPL. 6",

}

TY - JOUR

T1 - Optimizing chemoradiation in locally advanced non-small-cell lung cancer

AU - Curran, Walter J.

AU - Choy, Hak

PY - 2001

Y1 - 2001

N2 - Gemcitabine (Gemzar) has demonstrated activity in a broad range of solid tumors with good tolerance. In combined-modality therapy, gemcitabine has achieved response rates ranging between 30% and 60% in patients with non-small-cell lung cancer. Initial trials of gemcitabine and radiation showed that the fields and volume of radiation as well as the dose of gemcitabine should be managed carefully so as to optimize the radiosensitizing properties of this agent. The Cancer and Leukemia Group B conducted a phase III trial in patients with unresectable stage III non-small-cell lung cancer. A total of 187 patients were randomized to one of three cisplatin (Platinol)-based combinations (with gemcitabine,paclitaxel [Taxol], or vinorelbine [Navelbine]) as induction therapy followed by concomitant chemoradiation. At a median follow-up of 9 months, the median survival for all patients was 18 months and the median progression-free survival was 10 months. The trial demonstrated that the combination of gemcitabine and cisplatin could be administered successfully as induction therapy without affecting concurrent administration of gemcilabine/cisplatin with radiation.

AB - Gemcitabine (Gemzar) has demonstrated activity in a broad range of solid tumors with good tolerance. In combined-modality therapy, gemcitabine has achieved response rates ranging between 30% and 60% in patients with non-small-cell lung cancer. Initial trials of gemcitabine and radiation showed that the fields and volume of radiation as well as the dose of gemcitabine should be managed carefully so as to optimize the radiosensitizing properties of this agent. The Cancer and Leukemia Group B conducted a phase III trial in patients with unresectable stage III non-small-cell lung cancer. A total of 187 patients were randomized to one of three cisplatin (Platinol)-based combinations (with gemcitabine,paclitaxel [Taxol], or vinorelbine [Navelbine]) as induction therapy followed by concomitant chemoradiation. At a median follow-up of 9 months, the median survival for all patients was 18 months and the median progression-free survival was 10 months. The trial demonstrated that the combination of gemcitabine and cisplatin could be administered successfully as induction therapy without affecting concurrent administration of gemcilabine/cisplatin with radiation.

UR - http://www.scopus.com/inward/record.url?scp=0035291328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035291328&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 43

EP - 45

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3 SUPPL. 6

ER -